Clinical Trial Update: Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide [Phase 2]

View source ↗

Summary

Phase II trial protocol in chronic lymphocytic leukemia evaluates the FCR regimen (fludarabine, cyclophosphamide, rituximab) with lenalidomide. The study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: COMPLETED | Results posted: 2022-10-10